Southlake, TX – According to filings with the U.S. Securities and Exchange Commission, OncoNano Medicine is raising $68,407,469.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Martin Driscoll played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About OncoNano Medicine
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple and effective identifier of diseased tissue providing a foundation for the development of a broad range of highly targeted therapeutics and imaging agents. Our lead program, ONM-100, targets tumor acidosis to accurately differentiate cancer from healthy tissue for use in surgery.

To learn more about OncoNano Medicine, visit http://www.onconanomed.com/

Contact:
Martin Driscoll, Chief Executive Officer
682-285-1411
https://www.linkedin.com/in/marty-driscoll-a315015/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved